These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 24613520

  • 1. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.
    Vaccine; 2014 Apr 17; 32(19):2188-97. PubMed ID: 24613520
    [Abstract] [Full Text] [Related]

  • 2. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP.
    Vaccine; 2010 Mar 11; 28(12):2442-9. PubMed ID: 20074687
    [Abstract] [Full Text] [Related]

  • 3. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F, Jing X, Joshi M, Vasudevan A, Soto J, Li X, Choudhary A, Baichoo N, Resnick J, Ye Z, McCormick W, Weir JP.
    Influenza Other Respir Viruses; 2016 Mar 11; 10(2):134-40. PubMed ID: 26616263
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.
    Vaccine; 2011 Jul 26; 29(33):5421-3. PubMed ID: 21645575
    [Abstract] [Full Text] [Related]

  • 5. N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for Potency Testing and Immune Processing.
    An Y, Parsons LM, Jankowska E, Melnyk D, Joshi M, Cipollo JF.
    J Virol; 2019 Jan 15; 93(2):. PubMed ID: 30355697
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.
    Narayan K, Paduraru C, Blake T, Arunachalam AB.
    Front Immunol; 2023 Jan 15; 14():1128683. PubMed ID: 37457687
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance.
    Mandenius CF, Wang R, Aldén A, Bergström G, Thébault S, Lutsch C, Ohlson S.
    Anal Chim Acta; 2008 Aug 08; 623(1):66-75. PubMed ID: 18611459
    [Abstract] [Full Text] [Related]

  • 11. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
    Kuck LR, Byrne-Nash R, Gillis J, Bueter K, Couzens LK, Eichelberger MC, Rowlen KL.
    Vaccine; 2018 May 17; 36(21):2937-2945. PubMed ID: 29699789
    [Abstract] [Full Text] [Related]

  • 12. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM.
    Vaccine; 2011 Aug 11; 29(35):5911-8. PubMed ID: 21723354
    [Abstract] [Full Text] [Related]

  • 13. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.
    Vodeiko GM, Weir JP.
    Influenza Other Respir Viruses; 2012 May 11; 6(3):176-87. PubMed ID: 21902817
    [Abstract] [Full Text] [Related]

  • 14. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines.
    Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, Pilloud A, Serraille C, Devard N, Engel O, Sodoyer R, Moste C.
    J Virol Methods; 2011 Dec 11; 178(1-2):129-36. PubMed ID: 21907241
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A hemagglutinin quantification method for development of an influenza pandemic vaccine using size exclusion high performance liquid chromatography.
    Roh HS, Song HM, Yun BR, Kang HK, Choi KS, Park YJ, Kim DS, Kim SH, Mo IP, An BS, Ahn CY.
    Mol Med Rep; 2015 Apr 11; 11(4):2819-24. PubMed ID: 25482872
    [Abstract] [Full Text] [Related]

  • 17. Conformationally selective biophysical assay for influenza vaccine potency determination.
    Wen Y, Han L, Palladino G, Ferrari A, Xie Y, Carfi A, Dormitzer PR, Settembre EC.
    Vaccine; 2015 Oct 05; 33(41):5342-5349. PubMed ID: 26348403
    [Abstract] [Full Text] [Related]

  • 18. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.
    Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, Steven AC, King LR, Manischewitz J, McCormick W, Gupta RK, Golding H.
    Vaccine; 2011 Aug 05; 29(34):5657-65. PubMed ID: 21704111
    [Abstract] [Full Text] [Related]

  • 19. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
    Li C, Shao M, Cui X, Song Y, Li J, Yuan L, Fang H, Liang Z, Cyr TD, Li F, Li X, Wang J.
    Biologicals; 2010 Mar 05; 38(2):284-9. PubMed ID: 20074976
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.